Abstract: Objective: To assess the diagnostic value of combined detection of serum osteopontin (OPN) and tissue polypeptide specific antigen (TPS) in patients with gastric cancer (GC). Methods: Seventy patients with GC, 70 patients with superficial gastritis (SG) and 76 patients with atrophic gastritis (AG) were enrolled, and all these patients were pathologically confirmed; 50 healthy volunteers were served as controls. Serum OPN and TPS were detected by enzyme-linked immunosorbent assay (ELISA). The diagnostic value of OPN, TPS and CEA alone and in combination for GC were evalua-ted via sensitivity and specificity. Results: Serum levels of OPN and TPS were significantly increased (P<0.05) in GC patients than those in AG and SG patients and healthy controls. There was no significant difference (P>0.05) betweenserum levels of OPN and TPSin AG and SG patients and in healthy controls. The serum level of OPN in patients with GC on Ⅲ-Ⅳ stage was higher than that in patients on Ⅰ-Ⅱ stage (P<0.05). The serum level of OPN in GC patients with lymph node metastasis was higher than that in patients without lymph node metastasis (P<0.05). The serum level of TPS in patients with GC on Ⅲ-Ⅳ stage was lower than that in patients on Ⅰ-Ⅱ (P<0.05), and the serum level of TPS in GC patients with lymph node metastasis was lower than that in patients without lymph node metastasis (P<0.05). The area under the ROC (receiver operating characteristic) curve of combined detection of OPN, TPS and CEA was 0.849, the sensitivity was 71.4% and the specificity was 81.9% when the Youden Index was 53.3%. Conclusions: Combined detection of OPN, TPS and CEA may be useful in the differential diagnosis of GC and benign gastric diseases.

Key words: Osteopontin, Tissue polypeptide specific antigen, Gastric cancer, Diagnosis, Combined detection